Telcon RF Pharmaceutical (XKRX:200230) Interest Expense : ₩-3,760 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Telcon RF Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Telcon RF Pharmaceutical's interest expense for the three months ended in Dec. 2024 was ₩ -1,590 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-3,760 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Telcon RF Pharmaceutical's Operating Income for the three months ended in Dec. 2024 was ₩ 3,134 Mil. Telcon RF Pharmaceutical's Interest Expense for the three months ended in Dec. 2024 was ₩ -1,590 Mil. Telcon RF Pharmaceutical's Interest Coverage for the quarter that ended in Dec. 2024 was 1.97. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Telcon RF Pharmaceutical Interest Expense Historical Data

The historical data trend for Telcon RF Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telcon RF Pharmaceutical Interest Expense Chart

Telcon RF Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-2,848.54

-7,701.98

-1,062.74

-603.58

-3,759.90

Telcon RF Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-142.62	-328.83	-788.12	-1,052.87	-1,590.07

Telcon RF Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,760 Mil.

Telcon RF Pharmaceutical (XKRX:200230) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Telcon RF Pharmaceutical's Interest Expense for the three months ended in Dec. 2024 was ₩-1,590 Mil. Its Operating Income for the three months ended in Dec. 2024 was ₩3,134 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was ₩590 Mil.

Telcon RF Pharmaceutical's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2024 )	/	Interest Expense (Q: Dec. 2024 )
	=	-1	*	3134.162	/	-1590.074
	=	1.97

The higher the ratio, the stronger the company's financial strength is.

Telcon RF Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Telcon RF Pharmaceutical Inc (XKRX:200230) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

684, Dongtangiheung-ro, Giheung-gu, Gyeonggi-do, Yongin-si, KOR, 17102

Website

http://www.telcon.co.kr

Telcon RF Pharmaceutical Inc manufactures wireless communication equipment. It develops connectors for input and output ports, board-to-board, cable assembly, and board-to-mount used in wireless communication equipment. The company also supplies RF coaxial connectors. The company operates in the RF Division and Pharmaceuticals & Biotechnology segments. The majority of its revenue is generated from Pharmaceuticals & Biotechnology, which produces and sells liquids, tablets, pills, capsules, etc.

Telcon RF Pharmaceutical Headlines

No Headlines